CompletedPhase 2NCT03980925
Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.
Studying Gastroenteropancreatic neuroendocrine neoplasm
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Grupo Espanol de Tumores Neuroendocrinos
- Principal Investigator
- Rocío García-Carbonero, MD, PhDHospital Universitario 12 de Octubre
- Intervention
- Nivolumab(drug)
- Enrollment
- 37 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2023
Study locations (12)
- Institut Català d'Oncologia Badalona, Badalona, Barcelona, Spain
- Institut Català d'Oncologia l'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain
- Vall d'Hebron University Hospital, Barcelona, Spain
- Hospital Universitario 12 de Octubre, Madrid, Spain
- Hospital Universitario La Paz, Madrid, Spain
- Hospital Universitario Ramón y Cajal, Madrid, Spain
- MD Anderson Cancer Madrid, Madrid, Spain
- Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain
- Hospital Universitario Central de Asturias, Oviedo, Spain
- Hospital Universitario Marqués de Valdecilla, Santander, Spain
- Hospital Universitario Virgen del Rocío, Seville, Spain
- Hospital Universitario Miguel Servet, Zaragoza, Spain
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03980925 on ClinicalTrials.govOther trials for Gastroenteropancreatic neuroendocrine neoplasm
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06356467Influence of Tumour and Patient's Related Factors on the Response to Medical Treatments in Well Differentiated GEP-NENsIRCCS San Raffaele
- ACTIVE NOT RECRUITINGPHASE1NCT05262556NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine CarcinomasAmr Mohamed MD
- ACTIVE NOT RECRUITINGPHASE1NCT04750954Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine TumorsNational Cancer Institute (NCI)
- ACTIVE NOT RECRUITINGNANCT03012789Surgical Intervention and the NETestWren Laboratories LLC
See all trials for Gastroenteropancreatic neuroendocrine neoplasm →